Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection

NCT04510285 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT04510285
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04510285 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Terminated
Start date
August 10, 2020
Completion date
December 30, 2022
Enrollment
1 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer, esophageal neoplasms, esophageal tumor, esophagogastric tumors, gastric cancer, gastric tumor, gastroesophageal cancer, gastroesophageal junction adenocarcinoma, gastroesophageal junction cancer, gastroesophageal junction tumor